Eli Lilly’s market capitalization has climbed to approximately $960 billion as investors flock to its weight loss portfolio. In the most recent quarter, tirzepatide formulations Zepbound and Mounjaro collectively generated more than $10 billion in sales, driving a 54% year-over-year increase in total revenue. Over the past three years, Lilly’s share price has risen nearly 200%, reflecting both the safety of a diversified pharmaceutical business and the high growth trajectory of its obesity and diabetes treatments. Analysts forecast the global weight loss market could approach $100 billion by 2030, and Lilly’s late-stage oral candidate—submitted to regulators without accompanying dietary restrictions—promises additional upside if approved.

Lilly recently entered a multi-year research and licensing agreement with Nimbus Therapeutics to develop AI-driven oral therapies for obesity and metabolic diseases, underscoring its commitment to next-generation drug discovery. Concurrently, the company is in advanced discussions to acquire Ventyx Biosciences for over $1 billion. Ventyx’s lead oral candidates target inflammatory pathways in Crohn’s disease and rheumatoid arthritis and are in mid-stage trials for obesity-linked cardiovascular risk. These partnerships and potential mergers reinforce Lilly’s strategy to broaden its autoimmune and obesity treatment franchises and sustain long-term revenue growth.